Literature DB >> 20237316

SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage.

Peter Clark1, Isobel D Walker, Peter Langhorne, Lena Crichton, Andrew Thomson, Mike Greaves, Sonia Whyte, Ian A Greer.   

Abstract

To assess whether treatment with enoxaparin and low-dose aspirin, along with intensive pregnancy surveillance, reduces rate of pregnancy loss compared with intensive pregnancy surveillance alone in women with history of 2 or more consecutive previous pregnancy losses, a parallel group, multicenter, randomized controlled trial was performed in the United Kingdom and New Zealand. Participants (n = 294) presenting for initial antenatal care at fewer than 7 weeks' gestation with history of 2 or more consecutive previous pregnancy losses at 24 or fewer weeks' gestation and no evidence of anatomic, endocrine, chromosomal, or immunologic abnormality were randomly assigned to receive either enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with intense pregnancy surveillance or intense pregnancy surveillance alone from random assignment until 36 weeks' gestation. The primary outcome measure was pregnancy loss rate. Of the 147 participants receiving pharmacologic intervention, 32 (22%) pregnancy losses occurred, compared with 29 losses (20%) in the 147 subjects receiving intensive surveillance alone, giving an odds ratio of 0.91 (95% confidence interval, 0.52-1.59) of having a successful pregnancy with pharmacologic intervention. Thus, we observed no reduction in pregnancy loss rate with antithrombotic intervention in pregnant women with 2 or more consecutive previous pregnancy losses. The trial was registered at http://www.controlled-trials.com as ISRCTN06774126.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237316     DOI: 10.1182/blood-2010-01-267252

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.

Authors:  Ida Martinelli; Piero Ruggenenti; Irene Cetin; Giorgio Pardi; Annalisa Perna; Patrizia Vergani; Barbara Acaia; Fabio Facchinetti; Giovanni Battista La Sala; Maddalena Bozzo; Stefania Rampello; Luca Marozio; Olimpia Diadei; Giulia Gherardi; Sergio Carminati; Giuseppe Remuzzi; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

Review 3.  Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.

Authors:  Paulien G de Jong; Stef Kaandorp; Marcello Di Nisio; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2014-07-04

4.  Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.

Authors:  Elisabeth Pasquier; Luc de Saint Martin; Caroline Bohec; Céline Chauleur; Florence Bretelle; Gisèle Marhic; Grégoire Le Gal; Véronique Debarge; Frédéric Lecomte; Christine Denoual-Ziad; Véronique Lejeune-Saada; Serge Douvier; Michel Heisert; Dominique Mottier
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

5.  Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG (S1-Level, AWMF Registry No. 015/050, December 2013).

Authors:  B Toth; W Würfel; M K Bohlmann; G Gillessen-Kaesbach; F Nawroth; N Rogenhofer; C Tempfer; T Wischmann; M von Wolff
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-11       Impact factor: 2.915

6.  ANXA5: a key to unlock the mystery of the spectrum of placental-mediated pregnancy complications?

Authors:  Laura Ormesher; Ian A Greer
Journal:  Womens Health (Lond)       Date:  2016-02-22

Review 7.  Management of inherited thrombophilia in pregnancy.

Authors:  Laura Ormesher; Louise Simcox; Clare Tower; Ian A Greer
Journal:  Womens Health (Lond)       Date:  2016-07

8.  Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model.

Authors:  Jianzhong An; Magarya S Waitara; Michelle Bordas; Vidhyalakshmi Arumugam; Raymond G Hoffmann; Brian G Petrich; Uma Sinha; Paula E North; Rashmi Sood
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 9.  The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Marc A Rodger; Marisol T Betancourt; Peter Clark; Pelle G Lindqvist; Donna Dizon-Townson; Joanne Said; Uri Seligsohn; Marc Carrier; Ophira Salomon; Ian A Greer
Journal:  PLoS Med       Date:  2010-06-15       Impact factor: 11.069

10.  Outcomes in women receiving low-molecular-weight heparin during pregnancy.

Authors:  Maria T De Sancho; Sana Khalid; Paul J Christos
Journal:  Blood Coagul Fibrinolysis       Date:  2012-12       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.